top of page
Approved
Product
Target
Indication
Preclinical
Phase 1a
Phase 1b
Phase 2
Phase 3
NDA/BLA
Oncology-ADC
CLDN18.2
Solid Tumors
Nectin-4
Solid Tumors
PD-L1
Solid Tumors
EGFR
Solid Tumors
RET
Solid Tumors
Non-Oncology
TSLP
Asthma
Oncology- Other Modalities
FXI/FXIa
Thromboembolic disorders
bottom of page